1
|
Mancusi C, Izzo R, Losi MA, Barbato E, Trimarco V, Morisco C, Canciello G, Manzi MV, Rozza F, De Luca N, De Simone G, Trimarco B. P5457Assessment of carotid cross sectional area in hypertensive patients: phenotyping and prognostic validation in the campania salute network. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Increased intima media thickness (IMT) of common carotid artery (CA) is considered the hallmark of vascular hypertension-mediated target organ damage, even though vessel remodeling due to mechanical stress can be accompanied also by changes in diameter.
Purpose
We developed a method computing both diameter and IMT of CA, and assessed correlates and prognostic impact of carotid cross sectional area (CCSA) in a large registry of treated hypertensive patients.
Methods
We selected 7049 hypertensive patients of the Campania Salute Network registry free of overt cardiovascular (CV) disease and with available CA ultrasound (54±11 yrs; 57% male). CCSA was computed as:
π × [((CA diameter + 2 × (mean IMT)) / 2)]2 − π × [((CA diameter) / 2)]2.
Results
CCSA was considered high if >90th percentile of the sex-specific distribution (>48 mm2 in men and >41 mm2 in women). Higher CCSA correlated with older age, male sex, higher pulse pressure (PP), higher total and LDL cholesterol and presence of diabetes (p<0.01 for all). During a median follow-up of 45 months (IQR 19–92), 324 incident composite major and minor CV events occurred. In Cox regression analysis high CCSA was associated with more than 100% increased risk of incident CV events (p<0.0001, figure), independently of the effect of older age, male sex, PP>60mmHg, presence of left ventricular hypertrophy (LVH), carotid plaque (CP), and less anti-RAS therapy (p<0.05 for all).
Conclusions
In treated hypertensive patients, increased CCSA is associated with worse metabolic and lipid profile and predict incident CV events, independently of high PP, presence of LVH and CP.
Collapse
Affiliation(s)
- C Mancusi
- Federico II UNiversity of Naples, Naples, Italy
| | - R Izzo
- Federico II UNiversity of Naples, Naples, Italy
| | - M A Losi
- Federico II UNiversity of Naples, Naples, Italy
| | - E Barbato
- Federico II UNiversity of Naples, Naples, Italy
| | - V Trimarco
- Federico II UNiversity of Naples, Naples, Italy
| | - C Morisco
- Federico II UNiversity of Naples, Naples, Italy
| | - G Canciello
- Federico II UNiversity of Naples, Naples, Italy
| | - M V Manzi
- Federico II UNiversity of Naples, Naples, Italy
| | - F Rozza
- Federico II UNiversity of Naples, Naples, Italy
| | - N De Luca
- Federico II UNiversity of Naples, Naples, Italy
| | - G De Simone
- Federico II UNiversity of Naples, Naples, Italy
| | - B Trimarco
- Federico II UNiversity of Naples, Naples, Italy
| |
Collapse
|
2
|
Lønnebakken MT, Mancusi C, Losi MA, Gerdts E, Izzo R, Manzi MV, De Luca N, de Simone G, Trimarco B. Weight loss facilitates reduction of left ventricular mass in obese hypertensive patients: The Campania Salute Network. Nutr Metab Cardiovasc Dis 2019; 29:185-190. [PMID: 30559043 DOI: 10.1016/j.numecd.2018.10.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Revised: 10/23/2018] [Accepted: 10/24/2018] [Indexed: 02/07/2023]
Abstract
BACKGROUND AND AIMS Reduction of left ventricular mass index (LVMi) during antihypertensive treatment is less likely to occur in obese subjects. The aim of the study was to assess whether weight loss influences reduction of LVMi in treated, obese, hypertensive patients. METHODS AND RESULTS From the Campania Salute Network registry, we identified 1546 obese hypertensive patients (50 ± 9 years, 43% women) with more than 12 months follow-up. Echocardiographic reduction of LVMi was considered as achievement of normal values (<47 g/m2.7 in women or <50 g/m2.7 in men) or a reduction of ≥10% during follow-up. Weight loss was considered as ≥5% reduction in body weight, and occurred in 403 patients (26%) during a median follow-up of 50 months (IQrange:31-93). Median weight loss was 8.6% (IQrange:6.5-12). Patients with weight loss had higher baseline body mass index (p < 0.05), while there was no difference in age, sex, duration of hypertension, prevalence of diabetes, metabolic syndrome and average blood pressure during follow-up. During follow-up, 152 patients (9.8%) exhibited reduction of LVMi. Reduction of LVMi was more frequent (12.9% vs 9.1%, p < 0.030) in patients losing weight than in those who did not. In logistic regression analysis, weight loss was associated with reduction of left ventricular mass index (OR 1.51 [95%CI 1.02-2.23], p = 0.039), independent of significant associations with younger age, lower average systolic blood pressure during follow-up, longer follow-up time and higher LVMi at baseline. CONCLUSION In treated obese hypertensive patients, weight loss during follow-up promotes significant reduction of LVMi, independent of baseline characteristics and blood pressure control.
Collapse
Affiliation(s)
- M T Lønnebakken
- Hypertension Research Center, Federico II University Hospital, Naples, Italy; Department of Clinical Science, University of Bergen, Bergen, Norway
| | - C Mancusi
- Hypertension Research Center, Federico II University Hospital, Naples, Italy; Department of Advanced Biomedical Sciences, Naples, Italy
| | - M A Losi
- Hypertension Research Center, Federico II University Hospital, Naples, Italy; Department of Advanced Biomedical Sciences, Naples, Italy
| | - E Gerdts
- Hypertension Research Center, Federico II University Hospital, Naples, Italy; Department of Clinical Science, University of Bergen, Bergen, Norway
| | - R Izzo
- Hypertension Research Center, Federico II University Hospital, Naples, Italy; Department of Translational Medical Science Federico II University Hospital, Naples, Italy
| | - M V Manzi
- Hypertension Research Center, Federico II University Hospital, Naples, Italy; Department of Advanced Biomedical Sciences, Naples, Italy
| | - N De Luca
- Hypertension Research Center, Federico II University Hospital, Naples, Italy; Department of Advanced Biomedical Sciences, Naples, Italy
| | - G de Simone
- Hypertension Research Center, Federico II University Hospital, Naples, Italy; Department of Advanced Biomedical Sciences, Naples, Italy.
| | - B Trimarco
- Hypertension Research Center, Federico II University Hospital, Naples, Italy; Department of Advanced Biomedical Sciences, Naples, Italy
| |
Collapse
|
3
|
Trimarco V, Battistoni A, Tocci G, Coluccia R, Manzi MV, Izzo R, Volpe M. Single blind, multicentre, randomized, controlled trial testing the effects of a novel nutraceutical compound on plasma lipid and cardiovascular risk factors: Results of the interim analysis. Nutr Metab Cardiovasc Dis 2017; 27:850-857. [PMID: 28965797 DOI: 10.1016/j.numecd.2017.08.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Revised: 07/14/2017] [Accepted: 08/07/2017] [Indexed: 01/06/2023]
Abstract
BACKGROUND AND AIMS The clustering of high levels of LDL cholesterol (LDL-C) and other risk factors represents a predisposing condition for atherosclerotic disease development. Cardiovascular prevention is based on effective control of these conditions. In adult subjects with mild hypercholesterolemia we compared in the real life the effects of a new combination of nutraceuticals on lipid and glucose metabolism and blood pressure with those of an established nutraceutical combination. METHOD AND RESULTS This multicenter, controlled, randomized, single-blind trial was designed to compare the effect of Armolipid Plus® versus that of LopiGLIK® on lipid and glucose levels and blood pressure (BP) in subjects with mild hypercholesterolemia not on statin therapy. Primary outcome was the proportion of subjects achieving therapeutic targets of LDL-C (<130 mg/dl); secondary outcomes were the effects on HDL-C, glycated haemoglobin and insulin levels. Data from an overall sample of 359 adult individuals (age 55.2 ± 11.1 years, women 57.7%, LDL-C 157.3 ± 22.6 mg/dl, HDL-C 50.7 ± 13.0 mg/dl) are reported. 72% of subjects treated with LopiGLIK® and 43% treated with Armolipid Plus® achieved the primary endpoint (p < 0.0001). Both treatments reduced plasma levels of total and LDL-C and triglycerides (p < 0.001 for all comparisons). The treatments also reduced systolic and diastolic blood pressure, plasma levels of glycated haemoglobin, insulin and HOMA index. The changes induced by LopiGLIK® in all these metabolic parameters were greater than those obtained with Armolipid Plus®. CONCLUSIONS The present analysis shows that LopiGLIK® may represent a more effective tool for clinical management of CV risk factors in subjects with mild hypercholesterolemia.
Collapse
Affiliation(s)
- V Trimarco
- Hypertension Research Center, Federico II University, Naples, Italy; Department of Neurosciences, Federico II University, Naples, Italy
| | - A Battistoni
- Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy
| | - G Tocci
- Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy; IRCCS Neuromed, Pozzilli, IS, Italy
| | | | - M V Manzi
- Hypertension Research Center, Federico II University, Naples, Italy
| | - R Izzo
- Hypertension Research Center, Federico II University, Naples, Italy.
| | - M Volpe
- Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, University of Rome Sapienza, Sant'Andrea Hospital, Rome, Italy; IRCCS Neuromed, Pozzilli, IS, Italy
| |
Collapse
|
4
|
Mancusi C, Losi MA, Izzo R, Canciello G, Manzi MV, Sforza A, De Luca N, Trimarco B, de Simone G. Effect of diabetes and metabolic syndrome on myocardial mechano-energetic efficiency in hypertensive patients. The Campania Salute Network. J Hum Hypertens 2016; 31:395-399. [PMID: 28032631 DOI: 10.1038/jhh.2016.88] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Revised: 10/11/2016] [Accepted: 11/14/2016] [Indexed: 01/16/2023]
Abstract
Reduced myocardial mechano-energetic efficiency (MEE), estimated as stroke volume/heart rate ratio per g of left ventricular (LV) mass (LVM), and expressed in μl s-1 g-1 (MEEi), is a strong predictor of cardiovascular (CV) events, independently of LV hypertrophy and other confounders, including type II diabetes (DM). Decreased MEEi is more frequent in patients with diabetes. In the present analysis we evaluated the interrelation among MEEi, DM and metabolic syndrome (MetS) in the setting of arterial hypertension. Hypertensive patients from the Campania Salute Network, free of prevalent CV disease and with ejection fraction >50% (n=12 503), were analysed. Coexistence of MetS and DM was ordinally categorized into 4 groups: 8235 patients with neither MetS nor DM (MetS-/DM-); 502 without MetS and with DM (MetS-/DM+); 3045 with MetS and without DM (MetS+/DM-); and 721 with MetS and DM (MetS+/DM+). After controlling for sex, systolic blood pressure, body mass index, relative wall thickness (RWT), antihypertensive medications and type of antidiabetic therapy, MEEi was 333 μl s-1 g-1 in MetS-/DM-, 328 in MetS-/DM+, 326 in MetS+/DM- and 319 in MetS+/DM+ (P for trend <0.0001). In pairwise comparisons (Sidak-adjusted), all conditions, except MetS-/DM+, were significantly different from MetS-/DM- (all P<0.02). No statistical difference was detected between MetS-/DM+ and MetS+/DM-. Both MetS and DM are associated with decreased MEEi in hypertensive patients, independently to each other, but the reduction is statistically less evident for MetS-/DM+. MetS+/DM+ patients have the lowest levels of MEEi, consistent with the alterations of energy supply associated with the combination of insulin resistance with insulin deficiency.
Collapse
Affiliation(s)
- C Mancusi
- Hypertension Research Center, Federico II University Hospital, Naples, Italy.,Department of Advanced Medical Bioscience, Federico II University Hospital, Naples, Italy
| | - M A Losi
- Hypertension Research Center, Federico II University Hospital, Naples, Italy.,Department of Advanced Medical Bioscience, Federico II University Hospital, Naples, Italy
| | - R Izzo
- Hypertension Research Center, Federico II University Hospital, Naples, Italy.,Department of Translational Medical Sciences, Federico II University Hospital, Naples, Italy
| | - G Canciello
- Hypertension Research Center, Federico II University Hospital, Naples, Italy.,Department of Advanced Medical Bioscience, Federico II University Hospital, Naples, Italy
| | - M V Manzi
- Hypertension Research Center, Federico II University Hospital, Naples, Italy.,Department of Translational Medical Sciences, Federico II University Hospital, Naples, Italy
| | - A Sforza
- Hypertension Research Center, Federico II University Hospital, Naples, Italy.,Department of Translational Medical Sciences, Federico II University Hospital, Naples, Italy
| | - N De Luca
- Hypertension Research Center, Federico II University Hospital, Naples, Italy.,Department of Translational Medical Sciences, Federico II University Hospital, Naples, Italy
| | - B Trimarco
- Hypertension Research Center, Federico II University Hospital, Naples, Italy.,Department of Advanced Medical Bioscience, Federico II University Hospital, Naples, Italy
| | - G de Simone
- Hypertension Research Center, Federico II University Hospital, Naples, Italy.,Department of Translational Medical Sciences, Federico II University Hospital, Naples, Italy
| |
Collapse
|
5
|
Izzo R, De Simone G, Trimarco V, Gerdts E, Giudice R, Manzi MV, Falomi E, De Luca N, Trimarco B. Hypertensive target organ damage predicts incident diabetes mellitus. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.2889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|